Erratum: Tranilast enhances the anti-tumor effects of tamoxifen on human breast cancer cells in vitro (Journal of Biomedical Science (2013) 20 (76) DOI:10.1186/1423-0127-20-76);Tranilast enhances the anti-tumor effects of tamoxifen on human breast cancer cells in vitro

Journal of Biomedical Science

Volumn 20, Issue 1, 2013, Pages

  Darakhshan, Sara ^a   Ghanbari, Ali ^b  

^a RAZI UNIVERSITY   (Iran)

^b KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apoptosis; Breast cancer; Tamoxifen; Tranilast; Transforming growth factor beta

Indexed keywords

LACTATE DEHYDROGENASE; MATRIGEL; TAMOXIFEN; TRANILAST; TRANSFORMING GROWTH FACTOR BETA; ANTHRANILIC ACID DERIVATIVE; PROTEIN BAX; PROTEIN BCL 2;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CELL INVASION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; NICK END LABELING; PRIORITY JOURNAL; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; WOUND HEALING; BIOSYNTHESIS; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MCF 7 CELL LINE; PATHOLOGY;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; ORTHO-AMINOBENZOATES; PROTO-ONCOGENE PROTEINS C-BCL-2; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84887559867     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-20-89     Document Type: Erratum

References (60)

1. The biochemistry of apoptosis. Hengartner MO, Nature 2000 407 770 776 10.1038/35037710 11048727
2. Apoptosis. A Link between cancer genetics and chemotherapy. Johnstone RW, Ruefli AA, Lowe SW, Cell 2002 108 153 164 10.1016/S0092-8674(02)00625-6 11832206 (Pubitemid 34161136)
3. Metastasis: a question of life or death. Mehlen P, Puisieux A, Nat Rev Cancer 2006 6 449 458 10.1038/nrc1886 16723991
4. Breast cancer chemoprevention: a review of selective estrogen receptor modulators. Johansen AM, Clin J Oncol Nurs 2005 9 317 320 10.1188/05.CJON.317- 320 15973842
5. Targeted therapies for breast cancer. Higgins MJ, Baselga J, Journal of Clinical Invest 2011 121 3797 3803 10.1172/JCI57152
6. Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer. Roberts CG, Millar EK, O'Toole SA, McNeil CM, Lehrbach GM, Pinese M, et al. Oncogene 2011 30 3186 3197 10.1038/onc.2011.36 21383694
7. TGF-beta signal transduction. Massague J, Annu Rev Biochem 1998 67 753 791 10.1146/annurev.biochem.67.1.753 9759503 (Pubitemid 28411144)
8. TGF-beta signaling and cancer: structural and functional consequences of mutations in Smads. Hata A, Shi Y, Massague J, Mol Med Today 1998 4 257 262 10.1016/S1357-4310(98)01247-7 9679244 (Pubitemid 28308583)
9. The pleiotropic roles of transforming growth factor beta in homeostasis and carcinogenesis of endocrine organs. Fleisch MC, Maxwell CA, Barcellos-Hoff MH, Endocr Relat Cancer 2006 13 379 400 10.1677/erc.1.01112 16728569 (Pubitemid 43886664)
10. Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-beta 1. Pierce DF Jr, Johnson MD, Matsui Y, Robinson SD, Gold LI, Purchio AF, et al. Genes Dev 1993 7 2308 2317 10.1101/gad.7.12a.2308 8253379 (Pubitemid 24003235)
11. Role of transforming growth factor Beta in human cancer. Elliott RL, Blobe GC, J Clin Oncol 2005 23 2078 2093 10.1200/JCO.2005.02.047 15774796 (Pubitemid 46211385)
12. Transforming growth factor β1 in ductal carcinoma in situ and invasive carcinomas of the breast. Walker RA, Dearing SJ, Eur J Cancer 1992 28 641 644 10.1016/S0959-8049(05)80116-9 1317202
13. Pharmacological properties of N-(3′, 4′-dimethoxycinnamonyl) anthranilic acid, a new antiatopic agent. Azuma H, Banno K, Yoshimura T, Br J Pharmacol 1976 58 483 488 10.1111/j.1476-5381.1976.tb08614.x 63304
14. The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts. Suzawa H, Kikuchi S, Arai N, Koda A, Jpn J Pharmacol 1992 60 91 96 10.1254/jjp.60.91 1282576
15. Inhibition of PDGF- and TGF-beta 1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats. Miyazawa K, Kikuchi S, Fukuyama J, Hamano S, Ujiie A, Atherosclerosis 1995 118 213 221 10.1016/0021-9150(95)05607-6 8770315 (Pubitemid 26011483)
16. Inhibitory effect of tranilast on activation and transforming growth factor beta 1 expression in cultured rat stellate cells. Ikeda H, Inao M, Fujiwara K, Biochem Biophys Res Commun 1996 227 322 327 10.1006/bbrc.1996.1508 8878516 (Pubitemid 26362805)
17. Inhibitory effects of tranilast on proliferation, migration, and collagen synthesis of human vascular smooth muscle cells. Fukuyama J, Miyazawa K, Hamano S, Ujiie A, Can J Physiol Pharmacol 1996 74 80 84 10.1139/y95-230 8963955 (Pubitemid 26127979)
18. Tranilast inhibits TGF-β1 secretion without affecting its mRNA levels in conjunctival cells. Ochiai H, Ochiai Y, Chihara E, Kobe J Med Sei 2001 47 203 209 (Pubitemid 34296720)
19. N-[3, 4- dimethoxycinnamoyl]-anthranilic acid (tranilast) suppresses microglial inducible nitric oxide synthase (iNOS) expression and activity induced by interferon-gamma (IFN-gamma). Platten M, Wick W, Wischhusen J, Weller M, Br J Pharmacol 2011 134 1279 1284
20. Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-activated protein kinase and transforming growth factor-beta pathways in human breast cancer cells. Buck MB, Pfizenmaier K, Knabbe C, Mol Endocrinol 2004 18 1643 1657 10.1210/me.2003-0278 15056732 (Pubitemid 38859573)
21. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. Gaverieli Y, Sherman Y, Ben-Sasson SA, J Cell Biol 1992 119 493 501 10.1083/jcb.119.3.493 1400587
22. Chrysin and its phosphate ester inhibit cell proliferation and induce apoptosis in Hela cells. Zhang T, Chen X, Qu L, Wu J, Cui R, Zhao Y, Bioorg Med Chem 2004 12 6097 6105 10.1016/j.bmc.2004.09.013 15519155 (Pubitemid 39440450)
23. Comparative measurament of spontaneous apoptosis in pediatric acute leukemia by different techniques. Savitskiy VP, Shman T, Potapnev MP, Cytometry 2003 56 16 22 14582133 (Pubitemid 38292612)
24. Apoptosis: identification of dying cell. Renvoize C, Biola A, Pallardy M, Breard J, Cell Biol Toxicol 1998 14 111 120 10.1023/A:1007429904664 9553722 (Pubitemid 28123601)
25. A specialized form of chromosomal DNA degradation induced by thymidylate stress in mouse sel FM3A. Ayusawa D, Arai H, Wataya Y, Seno T, Mutat Res 1988 200 221 230 10.1016/0027-5107(88)90086-3 2839770
26. Variation in patients of DNA damage induced in human colorectal tumor cells by 5-fluorodeoxyuridine: Implications for mechanism of recistance and cytotoxicity. Canman CE, Tang HY, Normolle DP, Lawrence TS, Maybaum J, Proc Natl Acad Sci USA 1992 89 10474 10478 10.1073/pnas.89.21.10474 1438236
27. Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. Oberhammer F, Wilson JW, Dive C, Morris ID, Hickman JA, Wakeling AE, Walker PR, Sikorska M, EMBO J 1993 12 3679 3684 8253089 (Pubitemid 23256455)
28. Bcl-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to theraphy. Reed J, Miyashita T, Takayama S, Wang HG, Sato T, Krajewski S, Aime- Sempe C, Bodrug S, Kitada S, Hanada M, J Cell Biochem 1996 60 23 32 10.1002/(SICI)1097-4644(19960101)60:1<23::AID- JCB5>3.0.CO;2-5 8825412 (Pubitemid 26047917)
29. The bcl-2 protein family: Arbiters of cell survival. Adam JM, Cory S, Science 1998 281 1322 1326 9735050 (Pubitemid 28406819)
30. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS, Endocrinology 2003 144 4562 4574 10.1210/en.2003-0567 12959972 (Pubitemid 37204856)
31. Antioestrogen-mediated cell cycle arrest and apoptosis induction in breast cancer and multiple myeloma cells. Renoir JM, Bouclier C, Seguin A, Marsaud V, Sola B, J Mol Endocrinol 2008 40 101 112 10.1677/JME-07-0143 18316469 (Pubitemid 351586820)
32. Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Thiantanawat A, Long BJ, Brodie AM, Cancer Res 2003 63 8037 8050 14633737 (Pubitemid 37466743)
33. Activation of nitric oxide synthase is involved in tamoxifen-induced apoptosis of human erythroleukemia K562 cells. Maccarrone M, Fantini C, Ranalli M, Melino G, Agro AF, FEBS Lett 1998 434 421 424 10.1016/S0014-5793(98)01026-6 9742967 (Pubitemid 29052269)
34. Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators. Stewart BW, Journal of National Cancer Institute 1994 86 1286 1296 10.1093/jnci/86.17.1286 (Pubitemid 24276790)
35. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Adams JM, Cory S, Curr Opin Immunol 2007 19 488 496 17629468 (Pubitemid 47487452)
36. Developmental regulation of bcl-2 family protein expression in the involuting mammary gland. Metcalfe AD, Gilmore A, Klinowska T, Oliver J, Valentijn AJ, Brown R, Ross A, MacGregor G, Hickman JA, Streuli CH, J Cell Sci 1999 112 1771 1783 10318769 (Pubitemid 29295053)
37. Tamoxifen-induced apoptosis in breast cancer cells related to down regulation of bcl-2, but not bax and bcl-XL, without alteration of p53 protein levels. Zhang GJ, Kimijima I, Onda M, Kanno M, Sato H, Watanabe T, Tsuchiya A, Abe R, Takenoshita S, Clin Cancer Res 1999 5 2971 2977 10537367 (Pubitemid 29493977)
38. Biochemical studies of apoptosis induced by tamoxifen in estrogen receptor positive and negative breast cancer cell lines. Salami S, Karami-Tehrani F, Clin Biochem 2003 36 247 253 10.1016/S0009-9120(03)00007-9 12810152 (Pubitemid 36694969)
39. Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor. Weng SC, Kashida Y, Kulp SK, Wang D, Brueggemeier RW, et al. Mol Cancer Ther 2008 7 800 808 10.1158/1535-7163.MCT-07- 0434 18413793 (Pubitemid 351551033)
40. The growth inhibition of human breast cancer cells by a novel syntheticbprogestin involves the induction of transforming growth factor beta. Colletta AA, Wakefield LM, Howell FV, Danielpour D, Baum M, Sporn MB, J Clin Invest 1991 87 277 283 10.1172/JCI114983 1985102
41. Role of Ras and Mapks in TGF beta signaling. Mulder KM, Cytokine Growth Factor Rev 2000 11 23 35 10.1016/S1359-6101(99)00026-X 10708950 (Pubitemid 30169723)
42. Response of normal and oncogenetransformed human mammary epithelial cells to transforming growth factor beta 1 (TGF-beta 1): lack of growth-inhibitory effect on cells expressing the simian virus 40 large-T antigen. Basolo F, Fiore L, Ciardiello F, Calvo S, Fontanini G, Conaldi PG, Toniolo A, Int J Cancer 1994 56 736 742 10.1002/ijc.2910560521 8314352 (Pubitemid 24086779)
43. Immunohistochemical staining for transforming growth factor β1 associates with disease progression in human breast cancer. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA, Cancer Res 1992 52 6949 6952 1458485 (Pubitemid 23006305)
44. Invasion and metastasis of a mammary tumor involves TGF-beta signaling. McEarchern JA, Kobie JJ, Mack V, Wu RS, Meade-Tollin L, Arteaga CL, et al. Int J Cancer 2001 91 76 82 10.1002/1097-0215(20010101)91:1<76::AID-IJC1012>3.0. CO;2-8 11149423
45. Tumour microenvironment: TGF beta: the molecular Jekyll and Hyde of cancer. Bierie B, Moses HL, Nat Rev Cancer 2006 6 506 520 10.1038/nrc1926 16794634 (Pubitemid 43980540)
46. The two faces of transforming growth factor beta in carcinogenesis. Roberts AB, Wakefield LM, Proc Natl Acad Sci U.S.A. 2003 100 8621 8623 10.1073/pnas.1633291100 12861075 (Pubitemid 36899145)
47. Autocrine TGF beta supports growth and survival of human breast cancer MDA-MB-231 cells. Lei XF, Bandyopadhyay A, Le T, Sun LZ, Oncogene 2002 21 7514 7523 10.1038/sj.onc.1205966 12386814 (Pubitemid 35305579)
48. Differential regulation of expression of three transforming growth factor/3 species in human breast cancer cell lines by estradiol. Arrick BA, Korc M, Derynck R, Cancer Res 1990 50 299 303 2295070 (Pubitemid 20041231)
49. Resveratrol Sensitizes Tamoxifen in Antiestrogen-Resistant Breast Cancer Cells with Epithelial Mesenchymal Transition Features. Shi XP, Miao S, Wu Y, Zhang W, Zhang XF, Ma HZ, Xin HL, Feng J, Wen AD, Li Y, Int J Mol Sci 2013 14 15655 15668 10.3390/ijms140815655 23896596
50. The type III TGF-beta receptor suppresses breast cancer progression. Dong M, How T, Kirkbride KC, Gordon KJ, Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR, Blobe GC, J Clin Invest 2007 117 206 217 10.1172/JCI29293 17160136 (Pubitemid 46048467)
51. Development of TGF-beta signalling inhibitors for cancer therapy. Yingling JM, Blanchard KL, Sawyer JS, Nat Rev Drug Discov 2004 3 1011 1022 10.1038/nrd1580 15573100 (Pubitemid 39642364)
52. Targeted Apoptotic Effects of Thymoquinone and Tamoxifen on XIAP Mediated Akt Regulation in Breast Cancer. Rajput S, Kumar BN, Sarkar S, Das S, Azab B, Santhekadur PK, Das SK, Emdad L, Sarkar D, Fisher PB, Mandal M, Plos One 2013 8 61342 10.1371/journal.pone.0061342 23613836
53. Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling. Kumar BN, Rajput S, Dey KK, Parekh A, Das S, Mazumdar A, Mandal M, BMC Cancer 2013 13 273 10.1186/1471-2407-13-273 23731702
54. ZD6474 Enhances Paclitaxel Antiproliferative and Apoptotic Effects in Breast Carcinoma Cells. Sarkar S, Mazumdar A, Dash R, Sarkar D, Fisher PB, et al. J Cell Physiol 2011 226 375 384 10.1002/jcp.22343 20665703
55. Tamoxifen and flaxseed alter angiogenesis regulators in normal human breast tissue in vivo. Aberg UW, Saarinen N, Abrahamsson A, Nurmi T, Engblom S, et al. PLoS One 2011 6 25720 10.1371/journal.pone.0025720 21984941
56. Tranilast inhibits cell proliferation and migration and promotes apoptosis in murine breast cancer. Subramaniam V, Chakrabarti R, Prud'homme GJ, Jothy S, Anticancer Drugs 2010 21 351 361 10.1097/CAD.0b013e328334992c 20145538
57. Tranilast inhibits the proliferation of uterine leiomyoma cells in vitro through G1 arrest associated with the induction of p21waf1 and p53. Shime H, Kariya M, Orii A, Momma C, Kanamori T, Fukuhara K, et al. J Clin Endocrinol Metab 2002 87 5610 5617 10.1210/jc.2002-020444 12466360 (Pubitemid 36034367)
58. Tranilast suppresses prostate cancer growth and osteoclast differentiation in vivo and in vitro. Sato S, Takahashi S, Asamoto M, Naiki T, Naiki-Ito A, Asai K, Shirai T, Prostate 2010 70 229 238 19790239
59. Tranilast, an anti-allergic drug, down-regulates the growth of cultured neurofibroma cells derived from neurofibromatosis type 1. Yamamoto M, Yamauchi T, Okano K, Takahashi M, Watabe S, Yamamoto Y, Tohoku J Exp Med 2009 217 193 201 10.1620/tjem.217.193 19282654
60. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Prud'homme GJ, Lab Invest 2007 87 1077 1091 10.1038/labinvest.3700669 17724448 (Pubitemid 47610581)